CHI Advances Infectious Disease Survey –
July/August 2006 (n=83)

1. Please classify your organization.
2. Please indicate the product area that best describes your organization’s primary involvement in infectious diseases.
3. How has your involvement in anti-infectives changed over the past 4 years?
4. Does your organization plan to change its level of involvement in infectious diseases in the future?
5. How many anti-infective products (drugs, vaccines, diagnostics) has your organization launched up to and including 2006?
6. How many new anti-infective products do you expect to launch in 2007 or 2008?
7. How many anti-infective products does your organization have in R&D?
8. Will the HIV antiretroviral market continue to expand, with new market opportunities?
9. What is the focus of your diagnostic research?
10. In the quest for an ideal influenza test, which is the most important feature?
11. Is the antibacterial market considered too risky for new players?
12. Is your organization involved in biodefense?
13. To what extent have federal biodefense incentives affected decision-making in your organization?
14. If new biodefense legislation (i.e., the Biodefense and Pandemic Vaccine and Drug Development Act, or BARDA) passes, will this affect decision-making in your organization?
15. Which of the following best describes how your organization values involvement in neglected disease work?
16. Is your organization involved in neglected disease work?
17. How important is collaboration to your organization’s business plan?
18. Which of the following best describes the primary mode of collaboration on which your organization relies?
19. How important do you consider collaborations to be?
20. What is your organization’s primary mode of collaboration?